What Chiesi Farmaceutici does

Chiesi Farmaceutici S.p.A. is a family-owned biopharmaceutical group founded in 1935 and headquartered in Parma, Italy, operating through three therapeutic franchises — Air (respiratory, including asthma and COPD, which generated €1,886M in FY2025, approximately 52% of revenue), Rare (rare and ultra-rare diseases including hereditary angioedema, Fabry disease, and HoFH, €906M with 22.3% YoY growth), and Care (specialty care including neonatology and transplantation, €904M). The company develops and commercializes clinically differentiated therapies including TRIMBOW extrafine-formulation triple therapy inhaler, EKTERLY (sebetralstat) — the first oral on-demand hereditary angioedema treatment acquired through the June 2026 KalVista acquisition — Elfabrio enzyme replacement therapy for Fabry disease, and LOJUXTA for HoFH.

Chiesi's technology platforms include extrafine formulation for enhanced lung deposition, the Carbon Minimal Inhaler program using low global warming potential propellants to cut inhaler carbon footprint by up to 90%, blood-brain barrier crossing platforms developed through Key2Brain and Aliada Therapeutics partnerships for CNS lysosomal storage disorders, and gene editing capabilities via the Arbor Biotechnologies partnership for rare genetic diseases. The group operates 31 commercial affiliates globally and exports to more than 100 countries, with manufacturing in Italy, France, and the UK (via Bespak for pMDI production).

The business model centers on prescription pharmaceutical sales priced through national reimbursement authorities and insurance payers, supplemented by milestone and royalty payments from development partners (a $25M milestone from Protalix BioTherapeutics followed EC approval of Elfabrio's E4W dosing regimen in March 2026). FY2025 consolidated revenue reached €3.625 billion (+8.2% CER) with EBITDA of €931M (25.7% margin), and R&D investment of €885M (24.4% of revenue) — the highest in company history. The group funded its largest acquisition to date, KalVista Pharmaceuticals at approximately $1.9 billion, from a €729M net cash position and is led by a new Chair (Maria Paola Chiesi, the first woman in the role in the company's 90-year history) with CFO Jean-Marc Bellemin serving as Interim Group CEO following the May 2026 departure of CEO Giuseppe Accogli.

Name

Chiesi Farmaceutici

Legal name

Chiesi Farmaceutici S.p.A.

Website

https://chiesi.com

Company type

Private

Founded year

1935

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Chiesi Farmaceutici is a family-owned biopharmaceutical group founded in 1935 in Parma, Italy, developing prescription therapies across respiratory (asthma/COPD), rare diseases (HAE, Fabry, HoFH), and specialty care (neonatology, transplantation). It operates 31 commercial affiliates globally with FY2025 revenue of €3.625 billion.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ), Asthma & Allergy-Related Pulmonary Care (HLAKANAD)

Keywords

• Respiratory pharmaceuticals
• Rare disease therapies
• Inhaled drug delivery
• Biopharmaceutical products
• Specialty care medicines

Headquarters

HQ city

Parma

HQ country

Italy

HQ region

Europe

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Product Sales — Respiratory (Air): Revenue from commercialization of inhaled respiratory therapies including triple therapy inhaler (BDP/FF/G), bronchodilators, and maintenance therapies for asthma and COPD. Generated €1,886 million in FY2025, up 3.9% YoY, with triple therapy growing 15.8% and compensating for generic competition on legacy products.
2. Product Sales — Rare Diseases (Rare): Revenue from commercialization of rare disease therapies including Elfabrio (Fabry disease), Lojuxta/lomitapide (HoFH), and EKTERLY/sebetralstat (HAE). Generated €906 million in FY2025, up 22.3% YoY, representing 50% of total Group growth in US, Europe, and international markets.
3. Product Sales — Specialty Care (Care): Revenue from specialty care products. Generated €904 million in FY2025, up 13.3% YoY in constant currency. Includes neonatology and transplantation therapies.
4. Milestone and Royalty Payments: Payments received from development and commercialization partners upon regulatory milestones and royalties on product sales. Protalix BioTherapeutics paid $25 million milestone following European Commission approval of Elfabrio E4W dosing regimen.
5. Collaboration Revenue: Revenue from cost reimbursement and collaboration arrangements with partners such as Gossamer Bio, generating $9.3 million in cost reimbursement reported in Q1 2026.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Core offering

Chiesi Farmaceutici researches, develops, manufactures, and commercializes prescription pharmaceutical products organized across three business units: Air (respiratory inhaled therapies for asthma and COPD), Rare (orphan therapies for hereditary angioedema, Fabry disease, HoFH, and other rare conditions), and Care (neonatology and transplantation specialty products). Key marketed products include TRIMBOW triple therapy inhaler, EKTERLY (sebetralstat), Elfabrio (pegunigalsidase alfa), and LOJUXTA (lomitapide).

Product overview

Chiesi Farmaceutici is a research-focused international biopharmaceutical group organized into three therapeutic area sub-brands: Air (respiratory health), Rare (rare and ultra-rare diseases), and Care (specialty care including neonatology and transplantation). The product portfolio includes marketed products such as TRIMBOW triple therapy inhaler for asthma, EKTERLY (sebetralstat) for hereditary angioedema (acquired 2026), Elfabrio for Fabry disease, and LOJUXTA (lomitapide) for HoFH. The pipeline includes metreleptin for lipodystrophy. Chiesi is also advancing Carbon Minimal Inhalers technology for environmentally sustainable respiratory drug delivery. The company operates as a certified B Corp and Benefit Corporation, targeting Net Zero GHG emissions by 2035.

Differentiator

Problem solved

Functional benefit

Brands

• Air: Respiratory health franchise focusing on asthma and COPD treatments including triple therapy inhalers.
• Rare
• Care
• EKTERLY (sebetralstat)
• TRIMBOW
• Elfabrio
• LOJUXTA (lomitapide)

Products and services

• TRIMBOW (BDP/FF/G triple therapy inhaler) Single-inhaler triple therapy combining beclometasone dipropionate, formoterol fumarate, and glycopyrronium in extrafine formulation for maintenance treatment of asthma and COPD in adults.
• EKTERLY (sebetralstat) First and only oral, on-demand plasma kallikrein inhibitor for hereditary angioedema attacks in adults and adolescents aged 12 and older. Approved in US, EU, UK, Switzerland, Australia, Singapore, and Japan. Acquired through the KalVista Pharmaceuticals acquisition completed June 2026.
• Elfabrio (pegunigalsidase alfa) Enzyme replacement therapy for Fabry disease, developed in partnership with Protalix BioTherapeutics using a plant cell-based expression system. Approved with bi-weekly dosing in the US and every-four-weeks dosing in the EU.
• LOJUXTA (lomitapide) Prescription oral therapy for Homozygous Familial Hypercholesterolaemia (HoFH). Originally approved in EU for adults since 2013; pediatric expansion approved in 2026. Reimbursed in 16 countries.
• Metreleptin (investigational) Investigational therapy for generalized and partial lipodystrophy with ongoing clinical studies including Phase 4 immunogenicity and Phase 3 studies.
• FOSTAIR (beclometasone/formoterol extrafine fixed-dose combination) Extrafine fixed-dose combination inhaler of beclometasone and formoterol for asthma and COPD maintenance treatment.
• Air (respiratory franchise) Therapeutic area brand encompassing Chiesi's inhaled respiratory therapies for asthma and COPD, including TRIMBOW triple therapy and FOSTAIR. Generated €1.886 billion in FY2025 (up 3.9% YoY).
• Rare (Chiesi Global Rare Diseases) Business unit focused on research, development, and commercialization of therapies for rare and ultra-rare conditions including Fabry disease, hereditary angioedema, HoFH, and lipodystrophy. Generated €906 million in FY2025 (up 22.3% YoY).
• Care (specialty care franchise) Specialty care franchise covering neonatology and transplantation therapies. Funded the BESS clinical trial on surfactant therapy for severe bronchiolitis. Generated €904 million in FY2025 (up 13.3% YoY).

Quantifiable outcome

• 56% reduction in Scope 1 and 2 GHG emissions vs 2019 baseline, toward Net Zero by 2035
• +6 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• KalVista PharmaceuticalscoreStrategic or Co-development Partner · 11 June 2026Chiesi completed acquisition of KalVista Pharmaceuticals for approximately $1.9 billion in June 2026. KalVista brings EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), approved in US, EU, UK, Japan and other markets. KalVista became a wholly owned subsidiary of Chiesi with shares delisted from Nasdaq.
• SalesforcecoreTechnology or Integration · 20 April 2026Chiesi Group selected Salesforce Agentforce Life Sciences AI platform in April 2026 to transform customer engagement and commercial operations. The platform enables AI-driven commercial, clinical, and patient engagement built on unified data platforms. Over 140 industry-leading pharma and life sciences organizations use Agentforce Life Sciences.
• BespakcoreStrategic or Co-development Partner · 11 March 2026Partnership expanded in March 2026 to increase pressurized Metered Dose Inhaler (pMDI) manufacturing capacity at Bespak's Holmes Chapel site in the UK for Chiesi's Carbon Minimal Inhaler program. Goal is to reduce inhaler carbon footprint by up to 90% through low-GWP propellants. Both companies share sustainability commitments with Chiesi targeting Net Zero by 2035 and Bespak holding SBTi-validated decarbonization targets.
• Protalix BioTherapeuticscoreStrategic or Co-development Partner · 9 March 2026Partnership for Elfabrio (pegunigalsidase alfa) enzyme replacement therapy for Fabry disease. European Commission approved 2mg/kg every-four-weeks dosing regimen in March 2026, triggering a $25 million milestone payment to Protalix. Chiesi Global Rare Diseases commercializes Elfabrio in Europe and internationally. The existing bi-weekly label is approved in the US.
• Key2BrainmajorStrategic or Co-development Partner · 1 January 2025Partnership to advance development of two recombinant enzymatic replacement therapies (ERTs) capable of crossing the blood-brain barrier for treatment of lysosomal storage disorders (LSD). Part of Chiesi's strategy to expand rare disease pipeline in 2025.
• Arbor BiotechnologiesmajorStrategic or Co-development Partner · 1 January 2025Partnership to develop gene-editing therapies for rare diseases, with initial commitment of $115 million and potential total deal value up to $2 billion. Includes access to ABO-101 for primary hyperoxaluria type 1 and broader gene editing platform capabilities. ABO-101 aims to offer a permanent cure for PH1.
• Aliada TherapeuticsmajorStrategic or Co-development Partner · 1 January 2025Partnership to advance blood-brain barrier (BBB) crossing platform technology for application in lysosomal storage disorders (LSD). Complements the Key2Brain partnership and strengthens Chiesi's CNS rare disease capabilities.
• Gossamer BiocoreStrategic or Co-development PartnerCollaboration with Gossamer Bio on seralutinib for pulmonary arterial hypertension, with Chiesi receiving cost reimbursement ($9.3 million in Q1 2026). Seralutinib is an inhaled drug for PAH that underwent Phase 3 PROSERA trial. Chiesi has commercial interest in the asset pending regulatory outcomes.
• UK Medical Research Council (MRC) and NIHRminorStrategic or Co-development PartnerCo-funders of the BESS clinical trial on surfactant therapy for severe bronchiolitis, conducted across 15 UK children's hospitals over 6 winter seasons (2019-2024). Chiesi Farmaceutici provided funding for the largest-ever randomized study of surfactant for bronchiolitis in 232 critically ill babies.
• JD Health and SPH Health CommerceminorChannel Partner/ Reseller/ DistributorAgreements with Chinese digital health platforms JD Health and SPH Health Commerce supporting Chiesi's product launches in China. Chiesi announced it launched more products in China over the past two years than in any other country.
• Secarna PharmaceuticalsminorStrategic or Co-development PartnerRNA-based collaboration with Secarna Pharmaceuticals for rare renal indications, announced by Protalix BioTherapeutics in January 2026 as part of its 2026 strategy while maintaining commercial partnership with Chiesi for Elfabrio.

Scale indicators18 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• GlaxoSmithKline (GSK): GSK is a global pharmaceutical leader with a dominant respiratory franchise (Trelegy triple therapy directly competes with TRIMBOW, plus Advair/Seretide and Ventolin). GSK competes directly with Chiesi's Air franchise in asthma and COPD markets globally, and is a broad incumbent across multiple therapeutic areas.
• AstraZeneca: AstraZeneca's respiratory franchise (Symbicort, Fasenra, Breztri triple therapy) directly competes with Chiesi in asthma and COPD. AZ's rare disease arm (Alexion) also competes in some specialty areas, making it a broad incumbent peer across both core Chiesi franchises.
• Sanofi: Sanofi's specialty care arm (formerly Genzyme) competes with Chiesi in rare diseases (Fabry disease with Fabrazyme competing with Elfabrio), and Dupixent competes in respiratory/inflammatory conditions. Broad incumbent with overlapping rare disease and respiratory franchises.
• Takeda Pharmaceutical: Takeda is a global pharmaceutical company with a major rare disease franchise inherited from the Shire acquisition, including hereditary angioedema treatments (Firazyr, Takhzyro) competing with EKTERLY. Direct competitor to Chiesi's HAE franchise and broader rare disease portfolio.

Direct peers

• Vertex Pharmaceuticals: Vertex is a specialty pharmaceutical company focused on serious diseases, particularly cystic fibrosis (respiratory) and rare genetic diseases including sickle cell disease. Similar mid-large cap specialty pharma business model with high-margin orphan drug franchises and similar R&D intensity profile.
• BioMarin Pharmaceutical: BioMarin is a rare disease-focused biopharmaceutical company developing therapies for genetic conditions including enzyme replacement therapies. Direct overlap with Chiesi's Rare franchise in enzyme replacement (Fabry disease via Elfabrio), HoFH, and other genetic disorders.
• Swedish Orphan Biovitrum (Sobi): Sobi is a Swedish-based specialty biopharmaceutical company focused on rare diseases, including hemophilia, autoimmune diseases, and rare genetic conditions. Direct peer to Chiesi Global Rare Diseases in serving rare disease communities with high-priced specialty therapies.
• UCB: UCB is a Belgian specialty biopharmaceutical company focused on immunology and neurology, with a similar mid-large cap European specialty pharma profile. Comparable in scale, therapeutic focus on specialty/specialist-driven markets, and strong European R&D heritage.
• Recordati Rare Diseases: Recordati is an Italian specialty pharmaceutical group with a dedicated rare diseases business unit, focused on metabolic, endocrine, and rare conditions. Similar Italian heritage, family-influenced ownership, and business model combining specialty pharma with rare disease franchises.

Emerging players

• Stallergenes Greer: Stallergenes Greer is a specialty biopharmaceutical company focused on allergen immunotherapy and respiratory allergy diagnosis/treatment. Adjacent competitor in respiratory allergy therapeutics with overlapping physician specialty audiences (allergists, pulmonologists).

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ChiesiGroup
• YouTubeyoutube.com/channel/UCbZVCWaklAKOjCRQkWtiLKg
• Facebookfacebook.com/chiesifarmaceutici
• LinkedInlinkedin.com/company/chiesi-group

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chiesi Farmaceutici